The nesvacumab/aflibercept combination, which was evaluated for treatment of DMO and nAMD, demonstrated a safe profile and a positive trend toward anatomic and Diabetic Retinopathy Severity Scale score improvement, but there were no visual gains versus monotherapy [ 96 , 97 ].
← all excerpts
Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data.
1
—
—